American Journal of Cancer

, Volume 4, Issue 4, pp 221–231 | Cite as

Front-line treatment of epithelial ovarian cancer

Focus on the medical oncologists’ perspective
Leading Article


Epithelial ovarian cancer is the leading cause of death among the gynecologic malignancies. Over the past decade, advances in the field of ovarian carcinoma have brought an improvement in survival. This article focuses on the front-line management of ovarian cancer. While management of this disease is multidisciplinary and access to a trained gynecologic oncology surgeon is important, this article summarizes the most important advances from the medical oncologists’ perspective. It also reviews the current standard of care based on disease stage, as well as areas of investigation in the front-line treatment of ovarian cancer.


Ovarian Cancer Paclitaxel Carboplatin Ovarian Carcinoma Epithelial Ovarian Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The authors have provided no information on sources of funding or on conflicts of interest directly relevant to the content of this review.


  1. 1.
    Jemal A, Murray T, Ward E, et al. Cancer Statistics, 2005. CA Cancer J Clin 2005; 55: 10–30PubMedCrossRefGoogle Scholar
  2. 2.
    Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74–108PubMedCrossRefGoogle Scholar
  3. 3.
    Ozols RF, Schwartz PS, Eifel PJ. Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma. In: DeVita VT, Hellman S, editors. Cancer: Principles and Practice of Oncology. Philadelphia (PA): Lippincott Williams and Wilkins, 2001: 1597–632Google Scholar
  4. 4.
    Ozols RF, Rubin SC. In epithelial ovarian cancer. In: Hoskins WJ, Perez CA, Young RC, editors. Principles and practice of gynecologic oncology. Philadelphia (PA): Lippincott-Raven Publishers, 1997: 919–86Google Scholar
  5. 5.
    Dupont NC, Berman ML. Surgical management of epithelial ovarian cancer: a review of the literature. Minerva Ginecol 2004Dec; 56(6): 547–56PubMedGoogle Scholar
  6. 6.
    vonGruen VE, Daly BJ. Futility: clinical decisions at the end-of-life in women with ovarian cancer. Gynecol Oncol 2005May; 97(2): 638–44CrossRefGoogle Scholar
  7. 7.
    Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 2002; 7Suppl. 5: 20–8PubMedCrossRefGoogle Scholar
  8. 8.
    Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stage I and stage II epithelial ovarian carcinoma: results of two prospective randomized trials. N Engl J Med 1990; 322: 1021–8PubMedCrossRefGoogle Scholar
  9. 9.
    DiSaia PJ, Creasman WT. Epithelial ovarian cancer. In: Clinical gynecologic oncology. St. Louis (MO): Mosby-Year Book, Inc., 1997: 282–350Google Scholar
  10. 10.
    Pfisterer J, Lortholary A, Kimmig R, et al. Paclitaxel/carboplatin vs paclitaxel/carboplatin followed by topotecan (TC-Top) in first-line treatment of ovarian cancer FIGO stages IIB-IV: interim results of a Gynecologic Cancer Intergroup Phase III Trial of the AGO Ovarian cancer Study Group and GINECO [abstract]. Proc Am Soc Clin Oncol 2003; 22: 446aCrossRefGoogle Scholar
  11. 11.
    FIGO Committee on Gynecologic Oncology, September 2003. Staging classifications and clinical practice guidelines of gynecologic cancers. Available from URL: [Accessed 2005 Aug 10]
  12. 12.
    Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary in volume 25 of the FIGO annual report on the results of treatment in gynecologic cancer. Int J Gynaecol Obstet 2003Oct; 83Suppl. 1: 135–66PubMedCrossRefGoogle Scholar
  13. 13.
    Griffiths CT. Surgical resection of tumor bulk in primary treatment of ovarian carcinoma. J Natl Cancer Inst Monogr 1975; 42: 101–4Google Scholar
  14. 14.
    Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with completely resected stage III ovarian cancer: a GOG Study. J Clin Oncol 2003; 21: 3194–200PubMedCrossRefGoogle Scholar
  15. 15.
    Young R, Chabner B, Hibbard S, et al. Advanced ovarian carcinoma: a prospective randomized trial of melphalan (L-PAM) versus combination chemotherapy. N Engl J Med 1978; 299: 1261–6PubMedCrossRefGoogle Scholar
  16. 16.
    Hoskins WJ, Bundy BN, Thigpen JT, et al. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 1992; 47: 159–66PubMedCrossRefGoogle Scholar
  17. 17.
    Mutch DG. Surgical management of ovarian cancer. Semin Oncol 2002; 29(1 Suppl. 1): 3–8PubMedCrossRefGoogle Scholar
  18. 18.
    Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002; 20: 1248–59PubMedCrossRefGoogle Scholar
  19. 19.
    Eisenkop SM, Spirtos NM, Montag DW, et al. The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol Oncol 1992; 47: 203–9PubMedCrossRefGoogle Scholar
  20. 20.
    Nguyen HN, Averette HE, Hoskins W, et al. National survey of ovarian carcinoma. Part V: the impact of physician’s specialty on patients’ survival. Cancer 1993; 72: 3663–70PubMedCrossRefGoogle Scholar
  21. 21.
    Junor EJ, Hole DJ, Gillis CR. Management of ovarian cancer: referral to a multidisciplinary team matters. Br J Cancer 1994; 70: 363–70PubMedCrossRefGoogle Scholar
  22. 22.
    Elit L, Bondy SJ, Paszat L, et al. Outcomes in surgery for ovarian cancer. Gynecol Oncol 2002; 87: 260–7PubMedCrossRefGoogle Scholar
  23. 23.
    van derBerg MEL, vanLent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis of advanced epithelial ovarian cancer. N Engl J Med 1995; 3332: 629–34Google Scholar
  24. 24.
    Rose PG, Nerenstone S, Brady M, et al. A phase III randomized study of interval secondary cytoreduction in patients with advanced stage ovarian carcinoma with suboptimal residual disease: a Gynecologic Oncology Group Study [abstract]. Proc Am Soc Clin Oncol 2002; 21: 802Google Scholar
  25. 25.
    Vergote IB, DeWever I, Decloedt J, et al. Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer. Semin Oncol 2000; 27: 31–6PubMedGoogle Scholar
  26. 26.
    Ansquer Y, Leblanc E, Clough K, et al. Neoadjuvant therapy for unresectable ovarian carcinoma: a French multicentre study. Cancer 2001; 91: 2329–34PubMedCrossRefGoogle Scholar
  27. 27.
    Schwartz PE, Rutherford TJ, Chambers JT, et al. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecol Oncol 1999; 72: 93–9PubMedCrossRefGoogle Scholar
  28. 28.
    Vergote I, DeWever I, Tjalma W, et al. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol 1998; 71: 431–6PubMedCrossRefGoogle Scholar
  29. 29.
    Ozols RF, Schwartz PS, Eifel PJ. In Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma. In: DeVita VT, Hellman S, editors. Cancer: principles and practice of oncology. Philadelphia (PA): Lippincott Williams and Wilkins, 2001: 1597Google Scholar
  30. 30.
    Colombo N, Chiari S, Maggioni A, et al. Controversial issues in the management of early epithelial ovarian carcinoma: conservative surgery and the role of adjuvant therapy. Gynecol Oncol 1994; 55: S47–51PubMedCrossRefGoogle Scholar
  31. 31.
    Young RC, Brady MF, Nieberg RK, et al. Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin: a Gynecologic Oncology Group Study. J Clin Oncol 2003; 21: 4350–5PubMedCrossRefGoogle Scholar
  32. 32.
    Young RC. Three cycles versus six cycles of adjuvant paclitaxel (Taxol)/Carboplatin in early stage ovarian cancer. Semin Oncol 2000; 27(3 Suppl. 7): 8–10PubMedGoogle Scholar
  33. 33.
    Young RC, Rose G, Lage J. A randomized phase III trial of three versus six cycles of carboplatin and paclitaxel as adjuvant treatment in early stage ovarian epithelial carcinoma: a GOG Study [abstract]. Gynecol Oncol 2003; 88: 156CrossRefGoogle Scholar
  34. 34.
    Vergote IB, Vergote-DeVos LN, Abeler VM, et al. Randomized trial comparing cisplatin with radioactive phosphorous or whole-abdomen irradiation as adjuvant treatment of ovarian cancer. Cancer 1992; 69: 741–9PubMedCrossRefGoogle Scholar
  35. 35.
    Trimbos JB, Parmar M, Vergote I, et al. International collaborative ovarian neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 2003; 95(2): 105–12PubMedCrossRefGoogle Scholar
  36. 36.
    Colombo N, Guthrie D, Chiari S, et al. International collaborative ovarian neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst 2003; 95: 125–32PubMedCrossRefGoogle Scholar
  37. 37.
    Trimbos JB, Vergote I, Bolis G, et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant Chemotherapy in Ovarian Neoplasm trial. J Natl Cancer Inst 2003; 95: 113–25PubMedCrossRefGoogle Scholar
  38. 38.
    McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique neoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989; 111: 273–9PubMedGoogle Scholar
  39. 39.
    Thigpen JT, Blessing JA, Ball H, et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a GOG study. J Clin Oncol 1994; 12: 1748–53PubMedGoogle Scholar
  40. 40.
    Rowinsky EK, Gilbert MR, McGuire WP, et al. Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 1991; 9: 1691–703Google Scholar
  41. 41.
    McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Engl J Med 1996; 334: 1–6PubMedCrossRefGoogle Scholar
  42. 42.
    Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000; 92: 699–708PubMedCrossRefGoogle Scholar
  43. 43.
    Muggia FM, Braly PS, Brady MF, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a GOG study. J Clin Oncol 2000; 18: 106–15PubMedGoogle Scholar
  44. 44.
    ICON Group, Parmar MKB, Adams M, Balestrino M, et al. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002; 360: 505–15CrossRefGoogle Scholar
  45. 45.
    Bookman MA, McGuire IIIWP, Kilpatrick D, et al. Carboplatin and Paclitaxel in ovarian carcinoma: a phase I study of the GOG. J Clin Oncol 1996; 14: 1895–902PubMedGoogle Scholar
  46. 46.
    Niejt JP, Engelholm SA, Tuxen MK, et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000; 18: 3084–92Google Scholar
  47. 47.
    DuBois A, Luck HJ, Meier W, et al. A randomized clinical trial of cisplatin/ paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003; 17: 1320–9CrossRefGoogle Scholar
  48. 48.
    Morgan Jr RJ, Alvarez RD, DK Armstrong, et al. NCCN practice guidelines in ovarian cancer. The National Comprehensive Cancer Center Network. VI.2003Google Scholar
  49. 49.
    Kaye SB, Piccart M, Aapro M, et al. Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer: an updated overview. Eur J Cancer 1997Nov; 33(13): 2167–70PubMedCrossRefGoogle Scholar
  50. 50.
    Vasey PA. Role of docetaxel in the treatment of newly diagnosed ovarian cancer. J Clin Oncol 2003May 15; 21(10 Suppl.): 136–44CrossRefGoogle Scholar
  51. 51.
    Stuart GC. First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer. Gynecol Oncol 2003Sep; 90(3 Pt 2): S8–15PubMedCrossRefGoogle Scholar
  52. 52.
    Copeland LJ, Bookman MA, Trimble E. Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group protocol GOG 182-ICON5. Gynecol Oncol 2003Aug; 90(2 Pt 2): S1–7PubMedCrossRefGoogle Scholar
  53. 53.
    Markman M. Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol 2003May; 4(5): 277–83PubMedCrossRefGoogle Scholar
  54. 54.
    Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclo phosphamide for stage III ovarian cancer. N Engl J Med 1996; 335: 1950–5PubMedCrossRefGoogle Scholar
  55. 55.
    Gadducci A, Camino F, Chiara S, et al. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced EOC: a randomized trial of the Gruppo Oncologico Nord-Ovest. Gynecol Oncol 2000; 76: 157–62PubMedCrossRefGoogle Scholar
  56. 56.
    Markman M, Bundy BN, Albert DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the GOG, SWOG and ECOG. J Clin Oncol 2001; 19: 1001–7PubMedGoogle Scholar
  57. 57.
    Armstrong DK, Bundy BN, Baergen R, et al. Randomized phase III study of intravenous paclitaxel and cisplatin versus intravenous paclitaxel, intraperitoneal cisplatin and intraperitoneal paclitaxel in optimal stage II epithelial ovarian cancer: A GOG Trial (GOG 172) [abstract]. Proc Am Soc Clin Oncol 2002; 21: 201aGoogle Scholar
  58. 58.
    Guastalla JP, Lhomme C, Kerbrat P, et al. Phase II trial of intraperitoneal carboplatin in ovarian carcinoma patients with macroscopic residual disease at second-look laparotomy. a multicentre study of the French Federation Nationale des Centres de Lutte Contre le Cancer. Ann Oncol 1994; 5: 127–32PubMedGoogle Scholar
  59. 59.
    Malmstrom H, Simonsen E, Westberg R. A phase II study of intraperitoneal carboplatin as adjuvant treatment in early-stage ovarian cancer patients. Gynecol Oncol 1994; 52: 20–5PubMedCrossRefGoogle Scholar
  60. 60.
    Fujiwara K, Sakuragi N, Suzuki S, et al. First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up. Gynecol Oncol 2003; 90: 637–43PubMedCrossRefGoogle Scholar
  61. 61.
    Levin L, Hryniuk WM. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 1987; 5: 756–67PubMedGoogle Scholar
  62. 62.
    Bruckner HW, Wallach R, Cohen CJ, et al. High-dose cisplatin for the treatment of refractory ovarian cancer. Gynecol Oncol 1981; 12: 64–7PubMedCrossRefGoogle Scholar
  63. 63.
    Barker GH, Wiltshaw E. Use of high-dose cis-dichlorodiammine platinum (II) [NSC-119875] following failure on previous chemotherapy for advanced carcinoma of the ovary. Br J Obstet Gynaecol 1981; 88: 1192–9PubMedCrossRefGoogle Scholar
  64. 64.
    Ozols RF, Ostchega Y, Meyers CE, et al. High-dose cisplatin in hypertonic saline in refractory ovarian cancer. J Clin Oncol 1985; 2: 1246–50Google Scholar
  65. 65.
    Aghajanian C, Fennelly D, Shapiro F, et al. Phase II study of “dose-dense” high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer. J Clin Oncol 1998; 16: 1852–60PubMedGoogle Scholar
  66. 66.
    Schilder RJ, Brady MF, Spriggs D, et al. Pilot evaluation of high-dose carboplatin and paclitaxel followed by high-dose melphalan supported by peripheral blood stem cells in previously untreated advanced ovarian cancer: a GOG study. Gynecol Oncol 2003; 88: 3–8PubMedCrossRefGoogle Scholar
  67. 67.
    Schilder RJ, Gallo JM, Millenson MM, et al. Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood stem-cell support as front-line therapy. J Clin Oncol 2001; 19: 1183–94PubMedGoogle Scholar
  68. 68.
    Stiff PJ, Vuem-Stone J, Lazarus HM, et al. High-dose chemotherapy and autologous stem-cell transplantation for ovarian cancer: an autologous blood and marrow transplant registry report. Ann Intern Med 2000Oct 3; 133(7): 504–15PubMedGoogle Scholar
  69. 69.
    Legros M, Dauplat J, Fleury J, et al. High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results. J Clin Oncol 1997Apr; 15(4): 1302–8PubMedGoogle Scholar
  70. 70.
    Cure H, Battista H, Guastalla JP, et al. Phase III randomized trial of high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients (pts) with responsive low-burden advanced ovarian cancer (AOC): preliminary results of a GINECO/FNCLCC/SFGM-TC study [abstract]. Proc Am Soc Clin Oncol 2001, 815aGoogle Scholar
  71. 71.
    Hakes TB, Chalas E, Hoskins WJ, et al. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecol Oncol 1992; 45: 284–9PubMedCrossRefGoogle Scholar
  72. 72.
    Bertelsen K, Jakobsen A, Stroyer J, et al. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer a Danish Ovarian Study Group trial (DACOVA). Gynecol Oncol 1993; 49: 30–6PubMedCrossRefGoogle Scholar
  73. 73.
    Markman M, Liu PY, Wilczynski S, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a SWOG and GOG trial. J Clin Oncol 2003; 21: 2460–5PubMedCrossRefGoogle Scholar
  74. 74.
    Markman M, Bookman MA. Second-line treatment of ovarian cancer. Oncologist 2000; 5(1): 26–35PubMedCrossRefGoogle Scholar
  75. 75.
    Young RC, Decker DG, Wharton JT, et al. Staging laparotomy in early ovarian cancer. JAMA 1983; 250: 3072–6PubMedCrossRefGoogle Scholar
  76. 76.
    Thigpen JT, Vance RB, Khansur T. Second-line chemotherapy for recurrent carcinoma of the ovary. Cancer 1993; 71Suppl. 4: 1559–64PubMedCrossRefGoogle Scholar
  77. 77.
    Harries M, Gore M. Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease. Lancet Oncol 2002Sep; 3(9): 537–45PubMedCrossRefGoogle Scholar
  78. 78.
    Gronlund B, Hogdall C, Hansen HH, et al. Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer. Gynecol Oncol 2001; 83: 128–34PubMedCrossRefGoogle Scholar
  79. 79.
    Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003; 361(9375): 2099–106PubMedCrossRefGoogle Scholar
  80. 80.
    tenBokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997; 15: 2183–93PubMedGoogle Scholar
  81. 81.
    Fennelly D, Aghajanian C, Shapiro F, et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997Jan; 15(1): 187–92PubMedGoogle Scholar
  82. 82.
    Niwa Y, Nakanishi T, Kuzuya K, et al. Salvage treatment with docetaxel for recurrent epithelial ovarian cancer. Int J Clin Oncol 2003Dec; 8(6): 343–7PubMedCrossRefGoogle Scholar
  83. 83.
    Creemers GJ, Bolis G, Gore M, et al. Topotecan, an active drug in the 2nd-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 1996; 14(12): 3056–61PubMedGoogle Scholar
  84. 84.
    Bookman MA, Malmstrom H, Bolis G, et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 1998Oct; 16(10): 3345–52PubMedGoogle Scholar
  85. 85.
    Rose PG, Blessing JA, Mayer AR, et al. Prolonged oral etoposide as second-line therapy for platinum resistant and platinum-resistant ovarian carcinoma: a GOG Study. J Clin Oncol 1998; 16: 405–10PubMedGoogle Scholar
  86. 86.
    Shapiro JD, Millward MJ, Rischin D, et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 1996Oct; 63(1): 89–93PubMedCrossRefGoogle Scholar
  87. 87.
    Friedlander M, Millward MJ, Bell D, et al. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann Oncol 1998Dec; 9(12): 1343–5PubMedCrossRefGoogle Scholar
  88. 88.
    Muggia FM, Hainsworth JD, Jeffers S, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997Mar; 15(3): 987–93PubMedGoogle Scholar
  89. 89.
    Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001Jul 15; 19(14): 3312–22PubMedGoogle Scholar
  90. 90.
    Righetti SC, Delia Torre G, Pilotti S, et al. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 1996Feb; 56(4): 689–93PubMedGoogle Scholar
  91. 91.
    Berchuck A, Bast JrRC. p53-Based gene therapy of ovarian cancer: magic bullet? Gynecol Oncol 1995; 59: 169–70PubMedCrossRefGoogle Scholar
  92. 92.
    Buller RE, Runnebaum IB, Karlan BY, et al. A phase I/II trial of rAd/p53 (SCH58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther 2002; 9: 553–66PubMedCrossRefGoogle Scholar
  93. 93.
    Buller RE, Shahin MS, Horowitz JA, et al. Long-term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500. Cancer Gene Ther 2002; 9: 567–72PubMedCrossRefGoogle Scholar
  94. 94.
    Berek JS, Schultes BC, Nicodemus CF. Biologic and immunologic therapies for ovarian cancer. J Clin Oncol 2003; 21(10S): 168s–74sPubMedCrossRefGoogle Scholar
  95. 95.
    Raymond E, Faivre S, Armand JP. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 2000; 60Suppl. 1: 15–23PubMedCrossRefGoogle Scholar
  96. 96.
    Schilder RJ, Kohn E, Sill MW, et al. Phase II trial of gefitinib in patients with recurrent ovarian or primary peritoneal cancer: Gynecology Oncology Group 170C [abstract]. Proc Am Soc Clin Oncol 2003; 22: 1814Google Scholar
  97. 97.
    Herbst RS. Erlotinib (Tarceva): an update on the clinical trial program. Semin Oncol 2003; (3 Suppl 7): 34—46Google Scholar
  98. 98.
    Bookman MA, Darcy KM, Clarke-Pearson D, et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the GOG. J Clin Oncol 2003Jan 15; 21(2): 283–90PubMedCrossRefGoogle Scholar
  99. 99.
    Burger RA, Sill M, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC) [abstract no. 5009]. A Gynecologic Oncology Group (GOG) Study. Proc Am Soc Clin Oncol 2005; 23: 16SGoogle Scholar
  100. 100.
    Abramson N, Stokes PK, Luke M, et al. Ovarian and papillary serous peritoneal carcinoma: pilot study with thalidomide. J Clin Oncol 2002; 20: 1147–9PubMedCrossRefGoogle Scholar
  101. 101.
    Hirte HW, Vergote IB, Jeffrey J, et al. An international multicentre phase III study of BAY 12-9566 (BAY) versus placebo in patients with advanced ovarian cancer responsive to primary surgery/paclitaxel and platinum containing chemotherapy [abstract no. 832]. Proc Am Soc Clin Oncol 2001; 20: 209aGoogle Scholar
  102. 102.
    DiSaia PJ, Bloss JD. Treatment of ovarian cancer: new strategies. Gynecol Oncol 2003; 90: S24–32PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  1. 1.Fox Chase Cancer CenterPhiladelphiaUSA

Personalised recommendations